AMBITION-cm Trial
anemia
ADVERSE EVENTS, THROMBOPHLEBITIS, ANEMIA
The AMBITION phase 3 trial was a noninferiority, randomized, controlled trial of a single, high-dose of AmBisome given with 14 days of flucytosine and fluconazole in comparison with the WHO standard of care as previously defined: 7 days amphotericin deoxycholate plus flucytosine, followed by 7 days of fluconazole [In addition, the AmBisome regimen was associated with significantly fewer adverse events including anemia, thrombophlebitis, and electrolyte abnormalities. Grade 3 or 4 anemia developed in 13.3% of participants on AmBisome compared with 39.1% in the control group (